Metro Biotech Begins Phase 1a Trial Dosing for NAD Booster MIB-725
Metro International Biotech, LLC (MetroBiotech), a member of the EdenRoc Sciences family focused on developing advanced therapies for age-related diseases, has announced that the first patients in Cohort 1 of its Phase 1a clinical trial for MIB-725 have received their initial doses.
Metro International Biotech, LLC (MetroBiotech), a clinical-stage metabolism company and part of the EdenRoc Sciences family, has announced a key milestone in its efforts to develop novel therapeutics for age-related diseases. The company has begun dosing patients in the first cohort of its Phase 1a clinical trial for MIB-725, a proprietary investigational drug designed to act as a powerful NAD (nicotinamide adenine dinucleotide) precursor.
MIB-725 has demonstrated promising NAD-boosting effects in preclinical studies, indicating its potential to support cellular energy production and metabolic health. This Phase 1a trial represents the first clinical evaluation of the compound in humans and will assess its safety, pharmacokinetics, metabolism, and effect on circulating NAD levels. The trial follows a single ascending dose (SAD) design, where patients receive progressively higher doses to determine tolerability and appropriate dosing for future studies.
The initial cohort includes eight participants, four of whom have already received their first doses of MIB-725. Encouragingly, no dose-limiting toxicities have been observed so far, and the study will proceed with the dosing of the remaining patients before moving to higher doses. If the Phase 1a trial is completed successfully, a follow-up multiple ascending dose study (Phase 1b) is planned at the same site.
“Commencing Phase 1 testing of our novel NAD booster is a pivotal step in our mission to develop a class of NAD precursors tailored to specific therapeutic needs,” said Dr. David Livingston, president and chief scientific officer of MetroBiotech. “This initial study will serve as the foundation for understanding MIB-725’s pharmacological profile, creating a vital database of safety, pharmacokinetics, and metabolic data that will inform the next stages of our clinical development program. We hope that the insights gained here will help guide our broader compound development and potentially provide early signals of clinical benefit.”
The long-term objective for MIB-725 is to investigate its potential as a treatment for chronic kidney disease (CKD) associated with aging—a condition for which NAD depletion has been implicated. MIB-725 is the second investigational candidate from MetroBiotech’s pipeline aimed at combating diseases driven by NAD decline and mitochondrial dysfunction.
MetroBiotech’s other lead candidate, MIB-626, is currently in Phase 2 clinical trials targeting a range of age-related and metabolic disorders, including neurodegenerative conditions, muscle loss, and cardiovascular complications. Both MIB-626 and MIB-725 have shown NAD-boosting capabilities in animal models, along with protective effects against inflammation, organ damage, and mitochondrial disease-associated symptoms.
What sets these compounds apart is their differential involvement in NAD biosynthesis pathways, allowing for more targeted and organ-specific therapeutic applications. This nuanced approach to NAD supplementation is a cornerstone of MetroBiotech’s strategy to create safe, effective, and personalized treatments for the aging population.
MetroBiotech is committed to pharmaceutical-grade drug development and adheres strictly to FDA regulatory standards. All clinical trials, including the ongoing MIB-725 Phase 1 and the MIB-626 Phase 2 studies, are conducted under Investigational New Drug (IND) applications approved by the U.S. Food and Drug Administration. This positions MetroBiotech as a standout player in the NAD therapeutic space, where many commercially available supplements lack the rigorous oversight and clinical validation required for FDA-regulated pharmaceuticals.
With a strong foundation in medicinal chemistry and large-scale manufacturing capabilities, MetroBiotech is well-equipped to bring high-purity, clinically tested NAD boosters to market. The company continues to focus on age-related diseases with high unmet medical needs, including muscle wasting, kidney dysfunction, neurodegenerative disorders, and even certain types of cancer.
By expanding the understanding and therapeutic potential of NAD biology, MetroBiotech aims to improve healthspan and quality of life for aging populations worldwide. As the Phase 1a trial of MIB-725 progresses, the company remains optimistic about the role this compound—and its growing NAD-focused pipeline—could play in transforming the future of age-related disease treatment.
